Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Free Cash Flow (2019 - 2025)

IDEAYA Biosciences (IDYA) has disclosed Free Cash Flow for 7 consecutive years, with -$90.8 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 26.01% to -$90.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$73.5 million through Dec 2025, up 70.78% year-over-year, with the annual reading at -$73.5 million for FY2025, 70.78% up from the prior year.
  • Free Cash Flow hit -$90.8 million in Q4 2025 for IDEAYA Biosciences, down from $142.2 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $142.2 million in Q3 2025 to a low of -$122.8 million in Q4 2024.
  • Historically, Free Cash Flow has averaged -$29.5 million across 5 years, with a median of -$26.6 million in 2022.
  • Biggest five-year swings in Free Cash Flow: plummeted 413.74% in 2024 and later surged 386.11% in 2025.
  • Year by year, Free Cash Flow stood at -$17.3 million in 2021, then plummeted by 35.38% to -$23.4 million in 2022, then fell by 2.25% to -$23.9 million in 2023, then tumbled by 413.74% to -$122.8 million in 2024, then grew by 26.01% to -$90.8 million in 2025.
  • Business Quant data shows Free Cash Flow for IDYA at -$90.8 million in Q4 2025, $142.2 million in Q3 2025, and -$63.8 million in Q2 2025.